Impact of antifungal prophylaxis. A prospective, multicenter, observational study in India (MISFIC)
Not Applicable
- Conditions
- Health Condition 1: null- All patients with newly diagnosed /relapsed AML who undergo induction or salvage chemotherapy and receive antifungal prophylaxis will be included in the study.
- Registration Number
- CTRI/2014/04/004544
- Lead Sponsor
- MSD PHARMA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 200
Inclusion Criteria
a) Patients with newly diagnosed / relapsed AML (Both adult and pediatric patients); if they had or were anticipated to have neutropenia, with an absolute neutrophil count of 500 cells per cubic millimeter or less, for 7 days or more, resulting from remission-induction chemotherapy for newly diagnosed, or the first relapse of AML
b) Willing to sign informed consent
Exclusion Criteria
a)Use of chemotherapy other than those mentioned.
b)Invasive fungal infection within the previous 6 months,
c)Clinically significant hepatic or renal dysfunction which precludes use of antifungal prophylaxis
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method